Hormonal
Loss-of-function mutations in the central melanocortin system (specifically MC4R, POMC, or AgRP pathways) consistently increase fat preference and decrease carbohydrate preference in both rodents and humans.
For individuals with specific genetic variants affecting the melanocortin system, there is a biological predisposition toward higher fat preference and lower carbohydrate preference. Recognizing this can help in selecting dietary strategies that align with these preferences or manage them through environmental control.
Therefore, loss-of-function mutations in the central melanocortin system consistently increased fat preference and reduced carbohydrate preference, in rodents and humans.
Why this rating
The paper cites consistent findings across multiple genetic models (human MC4R mutations, Pomc-null mice, Ay/a mice) showing the same directional change in preference.
Source
Neural and Molecular Mechanisms Involved in Controlling the Quality of Feeding Behavior: Diet Selection and Feeding Patterns
Tsutomu Sasaki · Nutrients · 2017
DOI 10.3390/nu9101151
More from this paper
- Modifying the sequence of macronutrient ingestion (specifically consuming protein before carbohydrates) improves post-prandial glycemic control by enhancing GLP-1 secretion and delaying gastric emptying, independent of total caloric intake.Good
- Fibroblast growth factor 21 (FGF21) acts as a specific negative feedback signal that reduces carbohydrate (sweet) preference in response to high sugar intake.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →